Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ) just issued a press release showing "Peregrine’s Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model" AND "Shows Peregrine’s Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models."
Keep in mind that these are "advancing toward Linical Trials" and the company is in the developmental stage of making targeted monoclonal antibodies for cancer and hapatitis C. This data is being presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR).
Here is the full press release. Shares are up 9% and this one is only a $1.15 stock after the jump. The 52-week trading range is $0.86 to $1.99; its market cap after the gain is $223 million. PPHM has almost no revenues and has a net book value upon last financial data of about $22.1 million.
Jon C. Ogg
April 16, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
